489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results

Clete Kushida; Colin Shapiro; Thomas Roth; Michael Thorpy; Russell Rosenberg; Bruce Corser; Akinyemi Ajayi; Jordan Dubow; David Seiden; Yves Dauvilliers

doi:10.1093/sleep/zsab072.488

Retour

489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results

Article de revue

Avec comité de lecture

489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results

Clete Kushida, Colin Shapiro, Thomas Roth, Michael Thorpy, Russell Rosenberg, Bruce Corser, Akinyemi Ajayi, Jordan Dubow, David Seiden et Yves Dauvilliers

Sleep (New York, N.Y.), Vol.44(Supplement_2), pp.A193-A193

03/05/2021

DOI: https://doi.org/10.1093/sleep/zsab072.488

Indicateurs

1 Consultations de la notice

Détails

Titre: 489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results
Créateurs - sans rôle: Clete Kushida - Stanford Sleep Medicine Center
Colin Shapiro - International Sleep Clinic
Thomas Roth - Henry Ford Hospital
Michael Thorpy - Albert Einstein College of Medicine
Russell Rosenberg - NeuroTrials Research
Bruce Corser - Sleep Management Institute
Akinyemi Ajayi - Florida Pediatric Research Institute
Jordan Dubow - Avadel Pharmaceuticals
David Seiden - Avadel Pharmaceuticals
Yves Dauvilliers - Hôpital Gui de Chauliac
Détails de publication: Sleep (New York, N.Y.), Vol.44(Supplement_2), pp.A193-A193
Identifiants: 99140189609311
Unité académique: Institut des Neurosciences de Montpellier - INM
Langue: English
Type de ressource: Journal article